Terms: = Lung cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Clinical Outcome
111 results:
1. A Nasal Swab Classifier to Evaluate the Probability of lung cancer in Patients With Pulmonary Nodules.
Lamb CR; Rieger-Christ KM; Reddy C; Huang J; Ding J; Johnson M; Walsh PS; Bulman WA; Lofaro LR; Wahidi MM; Feller-Kopman DJ; Spira A; Kennedy GC; Mazzone PJ
Chest; 2024 Apr; 165(4):1009-1019. PubMed ID: 38030063
[TBL] [Abstract] [Full Text] [Related]
2. Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology.
van der Sar IG; Wijsenbeek MS; Braunstahl GJ; Loekabino JO; Dingemans AC; In 't Veen JCCM; Moor CC
Respir Res; 2023 Nov; 24(1):271. PubMed ID: 37932795
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined Small-Cell lung cancer: A Retrospective Study.
Shi Z; Wei J; Sun W; Zeng X; Zhou H; Song Z
Clin Lung Cancer; 2023 Dec; 24(8):717-725.e1. PubMed ID: 37482500
[TBL] [Abstract] [Full Text] [Related]
4. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Nicholson BD; Oke J; Virdee PS; Harris DA; O'Doherty C; Park JE; Hamady Z; Sehgal V; Millar A; Medley L; Tonner S; Vargova M; Engonidou L; Riahi K; Luan Y; Hiom S; Kumar H; Nandani H; Kurtzman KN; Yu LM; Freestone C; Pearson S; Hobbs FR; Perera R; Middleton MR
Lancet Oncol; 2023 Jul; 24(7):733-743. PubMed ID: 37352875
[TBL] [Abstract] [Full Text] [Related]
5. lung cancer surgery for patients with reduced left ventricular ejection fraction: clinical outcomes and long-term survival.
Kim MS; Hong TH; Yun J; Kim HK; Choi YS; Kim J; Shim YM; Cho YH; Cho JH
Eur J Cardiothorac Surg; 2023 May; 63(5):. PubMed ID: 37099712
[TBL] [Abstract] [Full Text] [Related]
6. Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors.
Yan X; Liu P; Li D; Hu R; Tao M; Zhu S; Wu W; Yang M; Qu X
Int Immunopharmacol; 2022 Dec; 113(Pt A):109383. PubMed ID: 36330916
[TBL] [Abstract] [Full Text] [Related]
7. PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
Liu J; Chen H; Qiao G; Zhang JT; Zhang S; Zhu C; Chen Y; Tang J; Li W; Wang S; Tian H; Chen Z; Ma D; Tian J; Wu YL
Cancer Immunol Immunother; 2023 Apr; 72(4):881-893. PubMed ID: 36121452
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of clinical outcomes of Icotinib in Patients With clinically Diagnosed Advanced lung cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized clinical Trial.
Xu J; Liu Z; Bai H; Dong G; Zhong J; Wan R; Zang A; Li X; Li Q; Guo J; Du N; Zhong D; Huang Y; Lv Q; Zhang J; Zhao Y; Gao L; Li L; Zhang C; Zhao J; Li B; Liu Z; Yang Z; Ji D; Wang T; Duan J; Wang Z; Wang J
JAMA Oncol; 2022 Sep; 8(9):1328-1332. PubMed ID: 35862035
[TBL] [Abstract] [Full Text] [Related]
9. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract] [Full Text] [Related]
10. Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis.
Sunaga N; Koga Y; Hachisu Y; Yamaguchi K; Aikawa M; Kasahara N; Miura Y; Tsurumaki H; Yatomi M; Sakurai R; Maeno T; Hisada T
Can Respir J; 2022; 2022():3726395. PubMed ID: 35663496
[TBL] [Abstract] [Full Text] [Related]
11. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
[TBL] [Abstract] [Full Text] [Related]
12. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract] [Full Text] [Related]
13. Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions.
Jiang H; Meng L; Zhang H; Dai X; Zhang Q; Ju Z; Yu W; Ma L
BMC Cancer; 2021 Dec; 21(1):1284. PubMed ID: 34852776
[TBL] [Abstract] [Full Text] [Related]
14. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.
Yoneda H; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Ogino H; Otsuka K; Nishioka Y
BMC Pulm Med; 2021 Nov; 21(1):373. PubMed ID: 34781910
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic impact of spread through air spaces in lung adenocarcinoma.
Mantovani S; Pernazza A; Bassi M; Amore D; Vannucci J; Poggi C; Diso D; d'Amati G; Della Rocca C; Rendina EA; Venuta F; Anile M
Interact Cardiovasc Thorac Surg; 2022 Jun; 34(6):1011-1015. PubMed ID: 34662397
[TBL] [Abstract] [Full Text] [Related]
16. A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.
Noro R; Igawa S; Bessho A; Hirose T; Shimokawa T; Nakashima M; Minato K; Seki N; Tokito T; Harada T; Sasada S; Miyamoto S; Tanaka Y; Furuya N; Kaburagi T; Hayashi H; Iihara H; Okamoto H; Kubota K
Lung Cancer; 2021 Nov; 161():49-54. PubMed ID: 34536731
[TBL] [Abstract] [Full Text] [Related]
17. The effect of itraconazole on the clinical outcomes of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a randomized controlled study.
Mohamed AW; Elbassiouny M; Elkhodary DA; Shawki MA; Saad AS
Med Oncol; 2021 Feb; 38(3):23. PubMed ID: 33559053
[TBL] [Abstract] [Full Text] [Related]
18. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract] [Full Text] [Related]
19. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract] [Full Text] [Related]
20. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
Li M; Zeng C; Yao J; Ge Y; An G
Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
[TBL] [Abstract] [Full Text] [Related]
[Next]
